IPSC · Century Therapeutics, Inc. · Executive Compensation
$1.29
-0.10 (-6.88%)
At close · Nov 19
Return incl. dividend (before tax)
Market Cap
$250.60M
Shares
181.60M
Volume · Nov 19
109.88K
Avg daily vol (3M)
738.85K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Joseph Truitt | member of the Board | Appointed | 2026-09-09 |
|
Carlo Rizzuto, Ph.D.
“Dr. Rizzuto’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
board of directors | Resigned | 2025-12-29 |
| Dr. Han Lee | director | Appointed | 2025-12-09 |
| Dr. Martin Murphy | director | Appointed | 2025-12-09 |
| Brent Pfeiffenberger, Pharm.D. | Chairman of the Board | Appointed | 2025-08-14 |
| Douglas Carr | interim Principal Financial Officer | Appointed | 2025-07-07 |
| Adrienne Farid, Ph.D. | Chief Development Officer | Terminated | 2025-07-07 |
| Morgan Conn, Ph.D. | Chief Financial Officer | Terminated | 2025-07-07 |
| Morgan Conn, Ph.D. | Chief Financial Officer | Appointed | 2024-09-26 |
|
Michael C. Diem, M.D.
“Dr. Diem’s decision to resign from the Company was not the result of any disagreement with the Company on matters relating to the Company’s operations, policies or practices.”
|
Chief Financial Officer | Resigned | 2024-01-19 |
| Gregory Russotti | Chief Technology and Manufacturing Officer | Appointed | 2023-11-14 |
| Brent Pfeiffenberger | member of the Board | Appointed | 2023-11-14 |
| Brent Pfeiffenberger | President and Chief Executive Officer | Appointed | 2023-11-14 |
| Michael Diem | Chief Financial Officer | Appointed | 2023-04-17 |
| Gregory Russotti | Interim President and Chief Executive Officer | Appointed | 2023-04-17 |
|
Osvaldo Flores, Ph.D.
“There was no disagreement between Dr. Flores and the Company on any matter related to the Company’s operations, policies or practices that led to Dr. Flores’ resignation from the Board.”
|
member of the Board of Directors | Resigned | 2023-04-17 |
|
Osvaldo Flores, Ph.D.
“There was no disagreement between Dr. Flores and the Company on any matter related to the Company’s operations, policies or practices that led to Dr. Flores’ resignation from the Board.”
|
President and Chief Executive Officer | Resigned | 2023-04-17 |
| Timothy P. Walbert | Class II Director | Appointed | 2022-10-03 |
| Daphne Quimi | Class I Director | Appointed | 2022-10-03 |
| Eli Casdin | Class I Director | Resigned | 2022-10-03 |
Leadership
- Brent Pfeiffenberger CEO, Chairman
- Gregory Russotti, Ph.D. CEO
- Brent Pfeiffenberger, Pharm.D. Chairman
- Douglas Carr CFO
- Michael Diem CFO
- Morgan Conn, Ph.D. CFO
- Gregory Russotti CTO
- Alessandro Riva Board Member
- Dr. Han Lee Board Member
- Dr. Martin Murphy Board Member
- Han Lee Board Member
- Joseph Truitt Board Member
- Timothy P. Walbert Board Member
Key facts
CIK
1850119
CUSIP
15673T100
13F (30d)
115 filings
99 filers
Visit website
Investor relations